ReviewCurrent hematologic malignancy reports2011
Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
Review in Current hematologic malignancy reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.The American journal of surgical pathology · 2014Trial
- Ki-67 as a Marker to Differentiate Burkitt Lymphoma and Diffuse Large B-cell Lymphoma: A Literature Review.Cureus · 2024Review
- Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells.Clinical & translational immunology · 2024Article
- Burkitt-type lymphoma incidentally found as the cause of acute appendicitis: a case report and review of literature.Surgical case reports · 2021Article
- High-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a cervical mass.BMJ case reports · 2020Article
- Primary Intradural Extramedullary Spinal Burkitt's Lymphoma: A Case Report.International medical case reports journal · 2020Article
- Burkitt's lymphoma presenting as acute appendicitis: a case report.Journal of surgical case reports · 2018Article
- Diagnostic Dilemma in the Morphological Detection of Flower Cells in Lymphomas.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.American journal of hematology · 2017Article
- Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.Irish journal of medical science · 2016Article
- Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.Cancer research and treatment · 2015Article
- Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas.Genome medicine · 2015Article
- The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.Current hematologic malignancy reports · 2013Review
- Primary Gastric Atypical Burkitt Lymphoma: A Rare Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification has allowed further refinements with significant therapeutic implications, including the designation of a new provisional entity, "B-cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL." This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.